Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Gushchin, Vladimir A.; Dolzhikova, Inna V.; Shchetinin, Alexey M.; Odintsova, Alina S.; Siniavin, Andrei E.; Nikiforova, Maria A.; Pochtovyi, Andrei A.; Shidlovskaya, Elena V.; Kuznetsova, Nadezhda A.; Burgasova, Olga A.; Kolobukhina, Liudmila V.; Iliukhina, Anna A.; Kovyrshina, Anna V.; Botikov, Andrey G.; Kuzina, Aleksandra V.; Grousova, Daria M.; Tukhvatulin, Amir I.; Shcheblyakov, Dmitry V.; Zubkova, Olga V.; Karpova, Oksana V.; Voronina, Olga L.; Ryzhova, Natalia N.; Aksenova, Ekaterina I.; Kunda, Marina S.; Lioznov, Dmitry A.; Danilenko, Daria M.; Komissarov, Andrey B.; Tkachuck, Artem P.; Logunov, Denis Y.; Gintsburg, Alexander L.

doi:10.3390/vaccines9070779

Open AccessArticle

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

by

Vladimir A. Gushchin

^1,2,*,†

,

Inna V. Dolzhikova

^1,*,†

,

Alexey M. Shchetinin

¹

,

Alina S. Odintsova

¹

,

Andrei E. Siniavin

^1,3

,

Maria A. Nikiforova

¹

,

Andrei A. Pochtovyi

^1,2

,

Elena V. Shidlovskaya

¹,

Nadezhda A. Kuznetsova

¹,

Olga A. Burgasova

^1,4,5,

Liudmila V. Kolobukhina

^1,4

,

Anna A. Iliukhina

¹,

Anna V. Kovyrshina

¹,

Andrey G. Botikov

¹,

Aleksandra V. Kuzina

¹,

Daria M. Grousova

¹,

Amir I. Tukhvatulin

¹

,

Dmitry V. Shcheblyakov

¹

,

Olga V. Zubkova

¹,

Oksana V. Karpova

⁴,

Olga L. Voronina

¹

,

Natalia N. Ryzhova

¹,

Ekaterina I. Aksenova

¹

,

Marina S. Kunda

¹,

Dmitry A. Lioznov

^6,7,

Daria M. Danilenko

⁶

,

Andrey B. Komissarov

⁶

,

Artem P. Tkachuck

¹,

Denis Y. Logunov

^1,*,† and

Alexander L. Gintsburg

^1,8 Show full author list Hide full author list

¹

Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia

²

Department of Virology, Biological Faculty, Lomonosov Moscow State University, 119991 Moscow, Russia

³

Department of Molecular Neuroimmune Signalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia

⁴

Moscow Healthcare Department, 127006 Moscow, Russia

⁵

Department of Infectious Diseases, Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia

⁶

Smorodintsev Research Institute of Influenza, 197022 St. Petersburg, Russia

⁷

Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University, 197022 St. Petersburg, Russia

⁸

Department of Infectiology and Virology, Federal State Autonomous Educational Institution of Higher Education I M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119435 Moscow, Russia

^*

Authors to whom correspondence should be addressed.

^†

Equal contribution.

Vaccines 2021, 9(7), 779; https://doi.org/10.3390/vaccines9070779

Submission received: 12 June 2021 / Revised: 6 July 2021 / Accepted: 6 July 2021 / Published: 12 July 2021

(This article belongs to the Special Issue Vaccine Candidate against SARS-CoV-2)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B.1.1.7, B.1.617.3 and local genetic lineages B.1.1.141 (T385I), B.1.1.317 (S477N, A522S) with RBD mutations. For the B.1.351, P.1, and B.1.617.2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from “Sputnik V”-vaccinated retain neutralizing activity against VOC B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 as well as local genetic lineages B.1.1.141 and B.1.1.317 circulating in Moscow.

Keywords: COVID-19; SARS-CoV-2; vaccine; Sputnik V; VOC; virus neutralizing activity

Share and Cite

MDPI and ACS Style

Gushchin, V.A.; Dolzhikova, I.V.; Shchetinin, A.M.; Odintsova, A.S.; Siniavin, A.E.; Nikiforova, M.A.; Pochtovyi, A.A.; Shidlovskaya, E.V.; Kuznetsova, N.A.; Burgasova, O.A.; et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines 2021, 9, 779. https://doi.org/10.3390/vaccines9070779

AMA Style

Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, Pochtovyi AA, Shidlovskaya EV, Kuznetsova NA, Burgasova OA, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines. 2021; 9(7):779. https://doi.org/10.3390/vaccines9070779

Chicago/Turabian Style

Gushchin, Vladimir A., Inna V. Dolzhikova, Alexey M. Shchetinin, Alina S. Odintsova, Andrei E. Siniavin, Maria A. Nikiforova, Andrei A. Pochtovyi, Elena V. Shidlovskaya, Nadezhda A. Kuznetsova, Olga A. Burgasova, and et al. 2021. "Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants" Vaccines 9, no. 7: 779. https://doi.org/10.3390/vaccines9070779

APA Style

Gushchin, V. A., Dolzhikova, I. V., Shchetinin, A. M., Odintsova, A. S., Siniavin, A. E., Nikiforova, M. A., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Burgasova, O. A., Kolobukhina, L. V., Iliukhina, A. A., Kovyrshina, A. V., Botikov, A. G., Kuzina, A. V., Grousova, D. M., Tukhvatulin, A. I., Shcheblyakov, D. V., Zubkova, O. V., ... Gintsburg, A. L. (2021). Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines, 9(7), 779. https://doi.org/10.3390/vaccines9070779

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI